[1] Ogasawara K,Terada T,Katsura T,et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.Drug Metab Pharmacokinet,2010,25:190-199.
[2] 李冰,陈国凤,韩萍,等.聚乙二醇干扰素α-2a联合利巴韦林治疗丙型肝炎肝硬化代偿期患者的疗效与安全性分析.解放军药学学报,2011,27:496-498.
[3] Calvaruso V,Mazza M,Almasio PL. Pegylated-interferon-α(2a) in clinical practice:how to manage patients suffering from side effects.Expert Opin Drug Saf,2011,10:429-435.
[4] Druyts E,Thorlund K,Wu P,et al.Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents:a systematic review and meta-analysis.Clin Infect Dis,2013, 56:961-967.
[5] 潘蕾,魏欣,谢玉梅,等.聚乙二醇干扰素α-2a治疗慢性丙型肝炎病毒/乙型肝炎病毒共感染临床疗效.临床肝胆病杂志,2011, 27:84-85,95.
[6] Kose S,Senger SS,Ersan G,et al.Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.Clin Exp Nephrol,2013,17:115-119.
[7] 杨艳杰,王福,郭艳玲,等.长效干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察.现代中西医结合杂志,2011,20:2998-3000.
[8] Maluf DG,Archer KJ,Villamil F,et al.Hepatitis C virus recurrence after liver transplantation:biomarkers of disease and fibrosis progression.Expert Rev Gastroenterol Hepatol,2010,4:445-458.
[9] Ponziani FR,Gasbarrini A,Pompili M,et al.Management of hepatitis C virus infection recurrence after liver transplantation:an overview.Transplant Proc,2011,43:291-295.
[10] Marroni CA.Treatment of recurrent hepatitis C post-liver transplantation. Ann Hepatol,2010,9 Suppl:84-91.
[11] Hashemi N,Araya V,Tufail K,et al.An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation.World J Hepatol,2011,3:198-204.
[12] 张素梅,谢玉梅,张颖,等.粒细胞集落刺激因子联合聚乙二醇干扰素α-2a及利巴韦林治疗丙型肝炎肝硬化的疗效观察.临床肝胆病杂志,2013, 29:348-351.
[13] 姚正钢,邓秋月.小剂量普通干扰素联合利巴韦林治疗失代偿期丙型肝炎肝硬化疗效观察.齐齐哈尔医学院学报,2012,33:1131-1132.
[14] 李冰,陈国凤,韩萍,等.聚乙二醇干扰素 α-2a 联合利巴韦林治疗丙型肝炎肝硬化代偿期患者的疗效与安全性分析.解放军药学学报,2011,27:496-498.
[15] 魏欣,谢玉梅,陈琳,等.丙型肝炎肝硬化的“分级”及聚乙二醇干扰素α-2a联合利巴韦林的抗病毒治疗.临床肝胆病杂志,2011,27: 89-92. |
